Drug Profile
Bendamustine - Eagle Pharmaceuticals
Alternative Names: BELRAPZO; Bendamustine 500mL; Bendamustine 50mL; Bendamustine hydrochloride - Eagle Pharmaceuticals; Bendamustine hydrochloride ready-to-dilute; Bendamustine hydrochloride RTD; Bendamustine II; Bendamustine rapid infusion; Bendamustine RI; Bendamustine RTD; Bendamustine shorter-infusion; Bendeka; Bendeka® rapid infusion; EP-3101; EP-3102; RTD bendamustine; TREAKISYM; Treakisym; TREAKISYM® ready-to-dilute liquid formulation; TREAKISYM®rapid infusionLatest Information Update: 23 Jan 2024
Price :
$50
*
At a glance
- Originator Eagle Pharmaceuticals
- Developer Eagle Pharmaceuticals; SymBio Pharmaceuticals
- Class Antineoplastics; Benzimidazoles; Butyric acids; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules
- Mechanism of Action Alkylating agents; Antimetabolites; DNA cross linking agents
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- No development reported Solid tumours
Most Recent Events
- 18 Jan 2024 Eagle Pharmaceuticals has patent protection for Bendamustine in USA
- 17 Jan 2024 Eagle files lawsuits referencing bendamustine marketed by Slayback, Apotex, and Baxter each infringe one or more claims of the newly issued patents and requesting damages for any infringing sales of the respective accused products
- 25 May 2023 Chemical structure information added